11 / 13
Page 46
Journal of Gastrointestinal & Digestive System | ISSN: 2161-069X | Volume 8
Clinical Gastroenterology and Hepatology
14
th
International Conference on
August 29-30, 2018 | Toronto, Canada
Can use Golgi protein 73(GP73), as a serum biomarker for early surveillance of hepatocellular carcinoma
in the first stage and chronic liver diseases in Saudi Arabia patients
Randa Mohamed MA Farag
1
, Dujana AlAyobi, Hye-Joo Kwon, Khalid A Alsaleh
2
, Afaf EL-Ansary
and
Emad A Dawoud
3
1
Princess Nourah Bint Abdulrahman University, Kingdom Saudi Arabia
2
King Saud University, Kingdom Saudi Arabia
3
EL-Azher University and Tawam Hospital, UAE
T
his study was performed to quantify the expression of Golgi protein-73 (GP73) in healthy controls and in patients with liver
disease, and to evaluate the correlations between GP73 and other serum markers in different liver diseases. Study the sensitivity
and specificity of Golgi Glypican-73 (GP37) as new biomarker useful in early prediction for Hepatocellular Carcinoma in hepatitis
viruses (HBV, HCV) and in chronic liver Cirrhosis; Also in chronic liver diseases. Serum GP73 was measured in 478 healthy controls
and 296 patients with different types of liver disease. Quantitative hepatitis B virus (HBV) DNA was determined in two chronic
hepatitis B (CHB) groups. Other serum liver fibrosis markers were measured in the liver fibrosis group and α-fetoprotein (AFP) was
measured in hepatocellular carcinoma (HCC) group. The correlations between GP73 and these markers were evaluated. The GP73
value in hepatitis B-e-antigen (HBeAg)-positive CHB group, HBeAg-negative CHB group, liver fibrosis group and HCC group was
significantly higher (p<0.001) than that in healthy controls. GP73 showed significant correlation with other markers in the liver
fibrosis group and with AFP in the HCC group. Compared with healthy controls, GP73 in patients with liver disease was significantly
increased. With the progression of liver disease, GP73 showed a significantly increasing trend. These results suggest that GP73 might
be used as a serum marker for the diagnosis of liver diseases and for monitoring disease progression
randa792006@gmail.comJ Gastrointest Dig Syst 2018, Volume 8
DOI: 10.4172/2161-069X-C6-080